Agilent Technologies' stock surged 8.31% overnight following the release of its fiscal second-quarter financial results, which exceeded analyst expectations across key metrics.

The analytical lab technology company reported adjusted earnings per share of $1.49 for the quarter, beating the consensus estimate of $1.41. Revenue came in at $1.835 billion, also surpassing the expected $1.799 billion. The company cited broad-based strength across its end markets and strong operational execution as primary drivers for the results.

Furthermore, Agilent raised its full-year 2026 adjusted profit forecast to a range of $6.00 to $6.10 per share, up from its prior outlook of $5.90 to $6.04. The upward revision reflects strong demand for the company's medical tools and laboratory equipment. Management also highlighted continued momentum from GLP-1 drugs, which is driving approximately 20% year-to-date growth, and positive analyst sentiment, including a new Outperform rating from RBC Capital Markets.